U.S. patent application number 14/047780 was filed with the patent office on 2015-02-19 for progesterone antagonist and selective progesterone modulator in the treatment of excessive uterine bleeding.
This patent application is currently assigned to PregLem S.A.. The applicant listed for this patent is PregLem S.A.. Invention is credited to Bartholomeus C.J.M. Fauser, Ernest Loumaye.
Application Number | 20150051180 14/047780 |
Document ID | / |
Family ID | 39766931 |
Filed Date | 2015-02-19 |
United States Patent
Application |
20150051180 |
Kind Code |
A9 |
Fauser; Bartholomeus C.J.M. ;
et al. |
February 19, 2015 |
Progesterone Antagonist and Selective Progesterone Modulator in the
Treatment of Excessive Uterine Bleeding
Abstract
Progesterone antagonists and SPRM are useful to prepare a
medication for the treatment or the prophylaxis of excessive
uterine bleeding in women with spontaneous or iatrogenic
coagulation disorders such as thrombopenia, coagulation factor
deficiency or anti-coagulant therapy. Treatment will last from 1
day to 180 days.
Inventors: |
Fauser; Bartholomeus C.J.M.;
(AT Rotterdam, NL) ; Loumaye; Ernest;
(Plan-Les-Ouates/Geneva, CH) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
PregLem S.A. |
Plan-Les-Ouates |
|
CH |
|
|
Assignee: |
PregLem S.A.
Plan-Les-Ouates
CH
|
Prior
Publication: |
|
Document Identifier |
Publication Date |
|
US 20140100208 A1 |
April 10, 2014 |
|
|
Family ID: |
39766931 |
Appl. No.: |
14/047780 |
Filed: |
October 7, 2013 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
12596624 |
Mar 29, 2010 |
8569274 |
|
|
PCT/IB2008/000945 |
Apr 18, 2008 |
|
|
|
14047780 |
|
|
|
|
60907875 |
Apr 20, 2007 |
|
|
|
Current U.S.
Class: |
514/179 |
Current CPC
Class: |
A61P 5/00 20180101; A61P
15/00 20180101; A61K 31/57 20130101; A61P 7/02 20180101; A61P 5/36
20180101; A61P 7/04 20180101; A61K 31/573 20130101; A61P 7/00
20180101; A61K 31/567 20130101 |
Class at
Publication: |
514/179 |
International
Class: |
A61K 31/573 20060101
A61K031/573; A61K 31/57 20060101 A61K031/57 |
Claims
1-28. (canceled)
29. A kit comprising a composition that comprises a therapeutically
effective amount of a progesterone antagonist, a selective
progesterone receptor modulator (SPRM), or an active metabolite
thereof, wherein the progesterone antagonist or SPRM is selected
from the group consisting of CDB-2914, mifepristone, asoprisnil,
CDB-4124, onapristone, org33628, tanaproget, tanaproget-combo, 11
beta-((4-N,N-dimethylamino)-phenyl)-17 beta-hydroxy-18-methyl-17
alpha-propinyl-4,9(10)-estradien-3-one, 11
beta-((4-N,N-dimethylamino)-phenyl)-17 a beta-hydroxy-17a
alpha-propinyl-D-homo-4,9(10),16-estratrien-3-one, 11
beta-4-methoxyphenyl-17 beta-hydroxy-17
alpha-ethinyl-4,9(10)-estradien-3-one, 11 beta-(4-acetylphenyl)-17
beta-hydroxy-17 alpha-(prop-1-inyl)-4,9(10)estradien-3-one, 11
beta-(4-dimethylaminophenyl)-17 alpha-hydroxy-17
beta-(3-hydroxy-propyl)-13 alpha-methyl-4,9-gonadien-3-one, (Z)-11
beta-[4-(dimethylamino)phenyl]-17beta-hydroxy-17alpha-(3-hydroxy-1-propen-
yl)-estr-4-en-3-one-5, 11 beta-(4-acetylphenyl)-17 beta-hydroxy-17
alpha-(3-hydroxyprop-1-(Z)-enyl)-4, 9(10)-estradien-3-one, 11
beta-(4-cyanophenyl)-17 beta-hydroxy-17
alpha-(3-hydroxyprop-1-(Z)-enyl)-4-androsten-3-one, 11 beta, 19-(4-
(3-pyridinyl)-o-phenylene)-17 beta-hydroxy-17 alpha-(3-hydroxyprop-
1-(Z)-enyl)-4-androsten-3-one, and a pharmaceutically acceptable
salt of any of the progesterone antagonists or SPRMs, and wherein
the therapeutically effective amount of the progesterone
antagonist, the SPRM, an active metabolite thereof, or a
pharmaceutically acceptable salt thereof can treat excessive
uterine bleeding resulting from a coagulation disorder.
30. The kit of claim 29, wherein the active metabolite of
asoprisnil is J912 or J956.
31. The kit of claim 29, wherein the active metabolite of CDB-4124
is CDB-4453.
32. The kit of claim 29, wherein the active metabolite of CDB-2914
is selected from the group consisting of CBD-3877, CDB-3963,
CDB-3236, and CDB-4183.
33. The kit of claim 29, wherein the coagulation disorder is
hemophilia, von Willebrand's disease, hepatic function impairment,
thrombocytopenia, leukemia, disseminated intravascular coagulation,
bone marrow aplasia, or inadequate anticoagulation treatment.
34. The kit of claim 29, wherein the progesterone antagonist, the
SPRM, or active metabolite of the progesterone antagonist or the
SPRM is selected from the group consisting of CDB-2914,
mifepristone, CDB-4124, onapristone, org33628, 11
beta-((4-N,N-dimethylamino)-phenyl)-17 beta-hydroxy-18-methyl-17
alpha-propinyl -4,9(10)-estradien-3-one, 11
beta-((4-N,N-dimethylamino)-phenyl)-17 a beta-hydroxy-17a
alpha-propinyl-D-homo-4,9(10),16-estratrien-3-one, 11
beta-4-methoxyphenyl-17 beta-hydroxy-17
alpha-ethinyl-4,9(10)-estradien-3-one, 11 beta-(4- acetylphenyl)-17
beta-hydroxy-17 alpha-(prop-1-inyl)-4,9(10)estradien-3-one, 11
beta-(4-dimethylaminophenyl)-17 alpha-hydroxy-17
beta-(3-hydroxy-propyl)-13 alpha-methyl-4,9-gonadien-3-one, (Z)-11
beta-[4-(dimethylamino)phenyl]-17beta-hydroxy-17alpha-(3-hydroxy-1-propen-
yl)-estr-4-en-3-one-5, 11 beta-(4-acetylphenyl)-17 beta-hydroxy-17
alpha-(3 -hydroxyprop-1 -(Z)-enyl)-4, 9(10)-estradien-3 -one, 11
beta-(4- cyanophenyl)-17 beta-hydroxy-17
alpha-(3-hydroxyprop-1-(Z)-enyl)-4-androsten-3-one, 11 beta,
19-(4-(3 -pyridinyl)-o-phenylene)-17 beta-hydroxy-17
alpha-(3-hydroxyprop-1 -(Z)-enyl)-4-androsten-3-one, and a
pharmaceutically acceptable salt of any of the progesterone
antagonists or SPRMs.
35. The kit of claim 29, wherein the composition is for daily
administration, every other day administration, once a week
administration, once every month administration, or a one-time
administration.
36. The kit of claim 35, wherein the composition is for daily
administration.
37. The kit of claim 29, wherein the composition can be
administered over a period of 1 to 180 days.
38. The kit of claim 29, wherein the composition is for
administration during bleeding peaks or during menstruation.
39. The kit of claim 29, wherein the therapeutically effective
amount is between 0.1 to 1000 mg.
40. A kit comprising a composition that comprises a therapeutically
effective amount of CDB-2914, an active metabolite of CDB-2914, or
a pharmaceutically acceptable salt of CDB-2914, wherein the
therapeutically effective amount can treat excessive uterine
bleeding resulting from a coagulation disorder, and wherein the
active metabolite of CDB-2914 is selected from the group consisting
of CBD-3877, CDB-3963, CDB-3236, and CDB-4183.
41. The kit of claim 40, wherein the therapeutically effective
amount is between 1 to 15 mg CDB-2914 or an amount of the
pharmaceutically acceptable salt of CDB-2914 equivalent to 1 to 15
mg CDB-2914.
42. The kit of claim 40, wherein the therapeutically effective
amount is 10 mg CDB-2914, or an amount of the pharmaceutically
acceptable salt of CDB-2914 equivalent to 1 mg CDB-2914.
43. The kit of claim 40, wherein the composition is for oral
administration.
44. The kit of claim 40, wherein the coagulation disorder is
hemophilia, von Willebrand's disease, hepatic function impairment,
thrombocytopenia, leukemia, disseminated intravascular coagulation,
bone marrow aplasia, or inadequate anticoagulation treatment
45. The kit of claim 40, wherein the coagulation disorder is bone
marrow aplasia.
46. The kit of claim 40, wherein the composition is administered
over a period of 1 to 180 days.
47. A kit comprising a composition that comprises a therapeutically
effective amount of CDB-4124, CDB-4453, or a pharmaceutically
acceptable salt of CDB-4124 or CDB-4453, wherein the
therapeutically effective amount can treat excessive uterine
bleeding resulting from a coagulation disorder.
48. The kit of claim 47, wherein the therapeutically effective
amount is 25 mg CDB-4124 or an amount of a pharmaceutically
acceptable salt thereof equivalent to 25 mg CDB-4124.
49. The kit of claim 19, wherein the composition is an oral dosage
form.
50. The kit of claim 19 further comprises an instruction for use.
Description
FIELD OF THE INVENTION
[0001] Progesterone antagonists and SPRM are useful to prepare a
medication for the treatment or the prophylaxis of excessive
uterine bleeding in women with spontaneous or iatrogenic
coagulation disorders such as thrombopenia, coagulation factor
deficiency or anti-coagulant therapy. Treatment will last from 1
day to 180 days.
BACKGROUND OF THE INVENTION
[0002] Uterine bleeding when abnormal can lead to significant
anemia and can even be life-threatening. Anatomical causes such as
fibroid, polyps, endometrium carcinoma or endometrium hyperplasia
resulting from prolonged un-opposed oestrogens deserve specific
treatments which are progestins, or surgery like curettage,
endoscopic resection or hysterectomy.
[0003] Dysfunctional uterine bleeding disorders (dysfunctional or
abnormal uterine bleeding, metrorrhagia and menorrhagia,
hypermenorrhea) are forms of pathological bleeding that are not
attributable to organic changes in the uterus (such as, e.g.,
endometrial carcinoma, myomas, polyps, etc.), systemic coagulation
disorders, or a pathological pregnancy (e.g., ectopic pregnancy,
impending abortion) [American College of Obstetricians and
Gynecologists, 1982]. Such disorders are most frequent after
puberty or before menopause. Treatment is medical using oestrogens
and progestins. If not successful and patient does not wish to
preserve fertility, hysterectomy or endometrial ablation may be
performed.
[0004] Another group of patients in whom controlling abnormal
uterine bleeding is a clinical challenge is patients with severe
coagulation disorders. These coagulation disorders results from (i)
pro-coagulant protein deficiency due to genetic defect (e.g.
hemophilia or von Willebrand disease) or functional deficiency
(e.g. hepatic function impairment), (2) thrombocytopenia caused by
decreased bone marrow production of megakaryocytes (e.g. leukemia),
splenic sequestration or increased destruction of platelets (e.g.
disseminated intravascular coagulation), (3) bone marrow aplasia
resulting from oncological treatments such as chemotherapy and
total body irradiation, and (4) inadequate anticoagulation
treatment.
[0005] These conditions are difficult to manage because bleeding
can be very severe and these patients often have impaired general
condition with for example immunodeficiency in leukemia or bone
marrow aplasia. Specific treatment like platelet transfusion, blood
transfusion and coagulation factor administration are used to
attempt controlling bleeding. Oestrogens and progestins are also
used with relative success and possible side effects. Inducing
reversible castration by sustained administration of a GnRH agonist
has also been reported to be useful in some cases for preventing
severe bleeding prior to chemotherapy. Surgical intervention in
these patients with altered general condition and immuno-deficiency
are at risk.
[0006] Being able to medically treat patients with acute conditions
such as acute phase of leukemia or treat or prevent uterine
bleeding during the acute phase of iatrogenic bone marrow aplasia
or treat or prevent uterine bleeding in patients under
anticoagulation therapy for conditions banning the use of
oestrogens and/or progestins (e.g. thrombo-embolic conditions),
will meet a very significant medical need.
SUMMARY OF THE INVENTION
[0007] The present invention concerns a method of treating and/or
preventing excessive uterine bleeding resulting from a coagulation
disorder consisting essentially in administering a therapeutically
effective amount of a progesterone antagonist, a SPRM, or an active
metabolite thereof, to a woman in need thereof.
[0008] A further object of the present invention is to provide the
use of a progesterone antagonist, a SPRM, or an active metabolite
thereof for the preparation of a medicament in the treatment and/or
prevention of excessive uterine bleeding resulting from a
coagulation disorder, in a woman in need thereof.
[0009] The invention also contemplates kit for treating and/or
preventing excessive uterine bleeding resulting from a coagulation
disorder comprising a therapeutically effective amount of a
progesterone antagonist, a SPRM, or an active metabolite thereof
optionally with reagents and/or instructions for use.
DETAILED DESCRIPTION OF THE INVENTION
[0010] The present invention relates to a method of treating and/or
preventing excessive uterine bleeding resulting from a coagulation
disorder consisting essentially in administering a therapeutically
effective amount of a progesterone antagonist, a SPRM, or an active
metabolite thereof, to a woman in need thereof.
[0011] As used herein, "a" or "an" means "at least one" or "one or
more."
[0012] As used herein, the term "comprise" is generally used in the
sense of include, that is to say permitting the presence of one or
more features or components.
[0013] A "therapeutically effective amount" is an amount effective
to ameliorate, treat or prevent the symptoms, diseases or disorders
in a mammal, or prolong the survival of the subject being
treated.
[0014] The terms "treating and/or preventing" refer to both
therapeutic treatment and prophylactic or preventative measures.
Those women in need of treatment include those already suffering
from excessive uterine bleeding resulting from a coagulation
disorder as well as those in which said disorder is to be
prevented. Hence, the subject to be treated herein may have been
diagnosed as having said disorder or may be predisposed or
susceptible to said disorder.
[0015] The term "SPRM" stands for selective progesterone receptor
modulator and represents a class of progesterone receptor ligands
that exerts clinically relevant tissue-selective progesterone
agonist, antagonist, or partial (mixed) agonist/antagonist effects
on various progesterone target tissues in an in-vivo situation
depending on the biological action studied (Smith C L and O'Malley
B W, 2004, Coregulator function: a key to understanding tissue
specificity of selective receptor modulators in Endocr Rev
25:45-71.)
[0016] As used herein, "a progesterone receptor antagonist" or "a
progesterone antagonist" refers to a compound or agent that
inhibits the activity of the progesterone receptor.
[0017] "Administering", as it applies in the present invention,
refers to contact of a therapeutically effective amount of a
progesterone antagonist, a SPRM, or an active metabolite thereof,
to the subject, preferably a woman.
[0018] As used herein "excessive uterine bleeding resulting from a
coagulation disorder" refers to a category of uterine bleeding
disorders different from dysfunctional uterine bleeding disorders.
The endometrium of patients suffering from excessive uterine
bleeding resulting from a coagulation disorder is healthy.
Additionally, these patients do no systematically respond to
standard therapy such as progestin treatment, on the contrary to
patients suffering from bleedings resulting from dysfunctional
uterine bleeding disorders. That is probably the reason why
patients suffering from excessive uterine bleeding resulting have
been excluded from SPRM treatment described by Chwalsz Christopher
et al., in U.S. Pat. No. 6,451,780 B1, indicating that for experts
other therapeutic approaches as those currently available are be
needed.
[0019] Surprisingly, Applicants have shown that it is possible to
treat and/or prevent excessive uterine bleeding resulting from a
coagulation disorder by administering a therapeutically effective
amount of a progesterone antagonist, a SPRM or an active metabolite
thereof to a woman suffering form these disorders.
[0020] This method of treating and/or preventing excessive uterine
bleeding resulting from a coagulation disorder, controls uterine
bleeding during a period of up to 6 months or is initiated prior to
inducing thrombopenia/aplasia for preventing severe uterine
bleeding and is continued throughout symptoms period.
[0021] Progesterone antagonist and SPRM have been shown to be very
well tolerated. PA/SPRM administration is not associated with the
metabolic adverse effects observed with oestrogens and progestins,
nor with the castration symptoms induced by GnRH agonist
therapy.
[0022] Progesterone antagonists and SPRM have been shown to stop
uterine bleeding within a few days in organic conditions such as
uterus fibroid most likely through a direct endometrium effect.
Reference has been made to the use of SPRM in dysfunctional uterine
bleeding although no data have been published so far. All these
conditions are attributable to local disruption of the endometrium
integrity.
[0023] Surprisingly enough, it has been found that progesterone
antagonist/SPRM are able to reduce and stop uterine bleeding in
patients with normal endometrium but altered coagulation.
[0024] The progesterone antagonist or SPRM that are consider for
this invention are selected form the group comprising, but not
limited to, CDB2914, mifepristone, asoprisnil, proellex,
onapristone, org33628, tanaproget, tanaproget-combo, WAY 166989,
NSP 989, NSP-combo, and 11[beta]-benzaldoxime substituted SPRMs
such as, for example,
11[beta]-((4-N,N-Dimethylamino)-phenyl-17[beta]-hydroxy-17[alpha]-propiny-
l-4,9(10)-estradien-3-one-(RU-38486),
11[beta]-((4-N,N-dimethylamino)-phenyl)-17[beta]-hydroxy-18-methyl-17[alp-
ha]-propinyl-4,9(10)-estradien-3-one,
11[beta]-((4-N,N-dimethylamino)-phenyl)-17
[alpha][beta]-hydroxy-17a[alpha]-propinyl-D-homo-4,9(10),16-estratien-3-o-
ne,
11[beta]-p-methoxyphenyl-17[beta]-hydroxy-17[alpha]-ethinyl-4,9(10)-es-
tradien-3-one,
11[beta]-(4-acetylphenyl)-17[beta]-hydroxy-17[alpha]-(prop-1-inyl)-4,9(10-
)estradien-3-one,
11[beta]-(4-dimethylaminophenyl)-17[alpha]-hydroxy-17[beta]-(3-hydroxy-pr-
opyl)-13[alpha]-methyl-4,9-gonadien-3-one,
(Z)-11[beta]-[4-(dimethylamino)phenyl]-17[beta]-hydroxy-17[alpha]-(3-hydr-
oxy-1-propenyl)-estr-4-en-3-one-5, 11[beta],
19-(4-acetylphenyl)-17[beta]-hydroxy
-17[alpha]-(3-hydroxyprop-1-(Z)-enyl)-4, 9(10)-estradien-3-one,
11[beta], 19-(4-cyanophenyl)
-17[beta]-hydroxy-17[alpha]-(3-hydroxyprop-1-(Z)-enyl)-4-androsten-3-one
or 11[beta],
19-(4-(3-pyridinyl)-o-phenylene)-17[beta]-hydroxy-17[alpha]-(3-hydroxypro-
p-1-(Z)-enyl)-4-androsten-3-one,
17[alpha]-acetoxy-21-methoxy-11.beta.-[4-N,N-dimethylaminophenyl]-19-norp-
regna-4, 9-diene-3,20-dione (CDB-4124, Proellex.RTM.),
[0025] It is known that progesterone receptor existed as two
isoforms, full-length progesterone receptor isoform (PR-B) and its
shorter counterpart (PR-A). Recently, extensive studies have been
implemented on the progesterone receptor knockout mouse (PRKO,
lacking both the A- and B-forms of the receptors). These findings
provided great challenge for synthetic chemists to construct not
only selective progesterone receptor modulator (SPRM), but also
PR-A or PR-B selective progesterone receptor modulator.
[0026] Accordingly, also encompassed inthe present invention is the
use of PR-A or PR-B selective progesterone receptor modulator such
as the indole derivatives described in U.S. Pat. No. 7,183,309
(JIANG WEIQIN et al.) which disclosure is incorporated herein as a
whole.
[0027] The method of the invention also considers the
administration of a therapeutically effective amount of an active
metabolite of progesterone antagonist or of an active metabolite of
a SPRM. An "active metabolite" is a product produced through
metabolism in the body of a specified compound or salt thereof and
which exhibits the same biological activity as the specified
compound. Active metabolites of a progesterone antagonist or of a
SPRM may be identified using routine techniques known in the art
and their activities determined using tests such as those described
herein. Such metabolites may result for example from the oxidation,
reduction, hydrolysis, amidation, deamidation, esterification,
deesterification, enzymatic cleavage, and the like, of the
administered progesterone antagonist or SPRM. Accordingly, the
invention includes active metabolites of a progesterone antagonist
or a SPRM, including compounds produced by a process comprising
contacting a compound of this invention with a mammal for a period
of time sufficient to yield a metabolic product thereof. Such
metabolite may also be produced in vitro by oxidation, reduction,
hydrolysis, amidation, deamidation, esterification,
deesterification, or enzymatic cleavage of the corresponding
progesterone antagonist or SPRM.
[0028] Examples of active metabolites of progesterone antagonists
or SPRM are shown in the following table 1:
TABLE-US-00001 Progesterone antagonist/SPRM Active Metabolite
asoprisnil J912 J956 CDB-4124 CDB-4453 CDB-2914 CBD-3877, CDB-3963,
CDB-3236 and CDB-4183
[0029] According to this invention, the progesterone antagonist,
the SPRM or an active metabolite thereof will be administered,
preferably daily, by oral route for a period of 1 to 180 days.
During this treatment period, the administration can be stopped if
condition leading to uterine bleeding has been corrected e.g.
correct of of thrombocytopenia or stopping anticoagulation
treatment.
[0030] Alternatively, the progesterone antagonist, the SPRM or an
active metabolite thereof will be administered, every other day,
once a week or once every month, preferably, as a one-time
administration.
[0031] Usually, the progesterone antagonist, the SPRM or an active
metabolite thereof will be administered during bleeding peaks or
during menstruation in an amount sufficient to treat and/or prevent
excessive uterine bleeding which results from a coagulation
disorder.
[0032] Usually, the progesterone antagonist, the SPRM or an active
metabolite thereof is administered at a daily dose between 0.1 to
1000 mg. However, the appropriate dosage will depend on the
progesterone antagonist, the SPRM, or the active metabolite
thereof. In case the SPRM is CDB-2914, it will be administered at a
daily dose between 1 to 15 mg, most preferably between 5 to 10 mg
and even more preferably at 10 mg (per day).
[0033] Progesterone antagonist, the SPRM or an active metabolite
thereof for use in the method as described herein, are usually in
the form of a pharmaceutical composition that may contain one or
more pharmaceutically acceptable carriers, such as excipients,
carriers and/or auxiliaries which facilitate processing of the
active compounds into preparation which can be used
pharmaceutically.
[0034] Acceptable carriers, excipients, or stabilizers are
non-toxic to recipients at the dosages and concentrations employed,
and include buffers such as phosphate, citrate, and other organic
acids; antioxidants including ascorbic acid and methionine;
preservatives (such as octadecyldimethylbenzyl ammonium chloride;
hexamethonium chloride; benzalkonium chloride, benzethonium
chloride; phenol, butyl orbenzyl alcohol; alkyl parabens such as
methyl or propyl paraben; catechol; resorcinol; cyclohexanol;
3-pentanol; and m-cresol); low molecular weight (less than about 10
residues) polypeptides; proteins, such as serum albumin, gelatin,
or immunoglobulins; hydrophilic polymers such as
polyvinylpyrrolidone; amino acids such as glycine, glutamine,
asparagine, histidine, arginine, or lysine; monosaccharides,
disaccharides, and other carbohydrates including glucose, mannose,
or dextrins; chelating agents such as EDTA; sugars such as sucrose,
mannitol, trehalose or sorbitol; salt-forming counter-ions such as
sodium; metal complexes (e.g. Zn-protein complexes); and/or
non-ionic surfactants such as TWEEN.RTM., PLURONICS.RTM. or
polyethylene glycol (PEG).
[0035] The form of administration of the pharmaceutical composition
may be systemic or topical. For example, administration of such a
composition may be various parenteral routes such as vaginal,
rectal, subcutaneous, intravenous, intradermal, intramuscular,
intraperitoneal, intra-uterine, intranasal, transdermal, buccal
routes or via an implanted device, and may also be delivered by
peristaltic means. Preferably, the form of administration of the
pharmaceutical composition comprising the progesterone antagonist,
the SPRM or an active metabolite thereof is by oral administration,
followed by the vaginal route.
[0036] One variation of the present invention also foresees a
pharmaceutical composition suitable for delayed and controlled
release of the Progesterone antagonists and SPRM as defined in the
present invention. The Progesterone antagonists and SPRM, for
example, may be incorporated in a matrix of biocompatible polymer
allowing delayed and controlled release. All biocompatible
polymers, well known by those skilled in the art are potential
candidate to be used in this invention. Vaginal rings or
intra-uterine devices are also contemplated options.
[0037] Sustained-release preparations may be prepared. Suitable
examples of sustained-release preparations include semi permeable
matrices of solid hydrophobic polymers containing the progesterone
antagonist or SPRM, which matrices are in the form of shaped
articles, e.g. films, or microcapsules. Examples of
sustained-release matrices include polyesters, hydrogels (for
example, poly(2-hydroxyethyl-methacrylate), or poly(vinylalcohol)),
polylactides (U.S. Pat. No. 3,773,919), copolymers of L-glutamic
acid and [gamma] ethyl-L-glutamate, non-degradable ethylene-vinyl
acetate, degradable lactic acid-glycolic acid copolymers such as
the LUPRON DEPOT.TM. (injectable microspheres composed of lactic
acid-glycolic acid copolymer and leuprolide acetate), and
poly-D-(-)-3-hydroxybutyric acid.
[0038] The formulations to be used for in vivo administration must
be sterile. This is readily accomplished for example by filtration
through sterile filtration membranes.
[0039] It is understood that the suitable dosage of the
progesterone antagonist, the SPRM or an active metabolite thereof
of the present invention will be dependent upon the age, health,
and weight of the woman in need thereof, kind of concurrent
treatment, if any and the nature of the effect desired.
[0040] The appropriate dosage form will depend on the disease, the
progesterone antagonist, the SPRM, or an active metabolite thereof
and the mode of administration; possibilities include tablets,
capsules, lozenges, pills, dental pastes, suppositories, inhalants,
solutions, ointments, parenteral depots, vaginal rings and
intra-uterine delivery systems.
[0041] In cases where the progesterone antagonist, tLe SPRM, or an
active metabolite thereof is included in a solution, the
formulation may contain suspending agents, as for example,
ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and
sorbitan esters, microcrystalline cellulose, aluminum
metahydroxide, bentonite, agar-agar and tragacanth, or mixtures of
these substances, among others.
[0042] Useful intranasal formulations of progesterone antagonist,
the SPRM, or an active metabolite thereof may contain a stabilizers
and a surfactants. Among the pharmaceutically acceptable
surfactants are polyoxyethylene castor oil derivatives, such as
polyoxyethylene-glycerol-triricinoleate, also known as polyoxyl 35
caster oil (CREMOPHOR EL), or poloxyl 40 hydrogenated castor oil
(CREMOPHOR RH140) both available from BASF Corp.; mono-fatty acid
esters of polyoxyethylene (20) sorbitan, such as polyoxyethylene
(20) sorbitan monolaurate (TWEEN 80), polyoxyethylene monostearate
(TWEEN 60), polyoxyethylene (20) sorbitan monopalmitate (TWEEN 40),
or polyoxyethylene 20 sorbitan monolaurate (TWEEN 20) (all
available from ICI Surfactants of Wilmington, Del.); polyglyceryl
esters, such as polyglyceryl oleate; and polyoxyethylated kernel
oil (LABRAFIL, available from Gattefosse Corp.). Preferably, the
surfactant will be between about 0.01% and 10% by weight of the
pharmaceutical composition. Among the pharmaceutically useful
stabilizers are antioxidants such as sodium sulfite, sodium
metabisulfite, sodium thiosulfate, sodium formaldehyde sulfoxylate,
sulfur dioxide, ascorbic acid, isoascorbic acid, thioglycerol,
thioglycolic acid, cysteine hydrochloride, acetyl cysteine,
ascorbyl palmitate, hydroquinone, propyl gallate,
nordihydroguaiaretic acid, butylated hydroxytoluene, butylated
hydroxyanisole, alpha-tocopherol and lecithin. Preferably, the
stabilizer will be between about 0.01% and 5% by weight of the
pharmaceutical composition.
[0043] Suspensions may also include chelating agents such as
ethylene diamine tetraacetic acid, its derivatives and salts
thereof, dihydroxyethyl glycine, citric acid and tartaric acid
among others. Additionally, proper fluidity of a suspension can be
maintained, for example, by the use of coating materials such as
lecithin, by the maintenance of the required particle size in the
case of dispersions and by the use of surfactants, such as those
previously mentioned.
[0044] Solid dosage forms for oral administration include capsules,
tablets, pills, powders and granules. In such solid dosage forms,
the active compound may be mixed with at least one inert,
pharmaceutically acceptable excipient or carrier, such as sodium
citrate or dicalcium phosphate and/or (a) fillers or extenders such
as starches, lactose, sucrose, glucose, mannitol and silicic acid;
(b) binders such as carboxymethylcellulose, alginates, gelatin,
polyvinylpyrrolidone, sucrose and acacia; (c) humectants such as
glycerol; (d) disintegrating agents such as agar-agar, calcium
carbonate, potato or tapioca starch, alginic acid, certain
silicates and sodium carbonate; (e) solution retarding agents such
as paraffin; (f) absorption accelerators such as quaternary
ammonium compounds; (g) wetting agents such as cetyl alcohol and
glycerol monostearate;(h) absorbents such as kaolin and bentonite
clay; and (i) lubricants such as talc, calcium stearate, magnesium
stearate, solid polyethylene glycols, sodium lauryl sulfate and
mixtures thereof. In the case of capsules, tablets and pills, the
dosage form may also comprise buffering agents.
[0045] Solid compositions of a similar type may also be employed as
fillers in soft and hard-filled gelatin capsules using such
excipients as lactose or milk sugar as well as high molecular
weight polyethylene glycols and the like.
[0046] The solid dosage forms of tablets, capsules, pills and
granules can be prepared with coatings and shells such as enteric
coating and other coatings well-known in the pharmaceutical
formulating art. They may optionally contain opacifying agents and
may also be of a composition such that they release the active
ingredient(s) only, or preferentially, in a certain part of the
intestinal tract, optionally, in a delayed manner. Examples of
embedding compositions which can be used include polymeric
substances and waxes.
[0047] Liquid dosage forms for oral administration include
pharmaceutically acceptable emulsions, solutions, suspensions,
syrups and elixirs. In addition to the active compounds, the liquid
dosage forms may contain inert diluents commonly used in the art
such as, for example, water or other solvents, solubilizing agents
and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl
carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate,
propylene glycol, 1,3-butylene glycol, dimethyl formamide, oils (in
particular, cottonseed, groundnut, corn, germ, olive, castor and
sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene
glycols and fatty acid esters of sorbitan and mixtures thereof.
[0048] This invention also envisages the use of the progesterone
antagonist, the SPRM, or an active metabolite thereof in a
pharmaceutically acceptable salt form. Examples of such salts may
include sodium, potassium, calcium, aluminum, gold and silver
salts. Also contemplated are salts formed with pharmaceutically
acceptable amines such as ammonia, alkyl amines,
hydroxyalkylamines, N-methylglucamine and the like. Certain basic
compounds also form pharmaceutically acceptable salts, e.g., acid
addition salts. For example, pyrido-nitrogen atoms may form salts
with strong acid, while compounds having basic substituents such as
amino groups also form salts with weaker acids. Examples of
suitable acids for salt formation are hydrochloric, sulfuric,
phosphoric, acetic, citric, oxalic, malonic, salicylic, malic,
fumaric, succinic, ascorbic, maleic, pamoic, methanesulfonic and
other mineral and carboxylic acids well known to those skilled in
the art. The salts are prepared by contacting the free base form
with a sufficient amount of the desired acid to produce a salt in
the conventional manner. The free base forms may be regenerated by
treating the salt with a suitable dilute aqueous base solution such
as dilute aqueous NaOH, potassium carbonate, ammonia and sodium
bicarbonate. The free base forms differ from their respective salt
forms somewhat in certain physical properties, such as solubility
in polar solvents, but the acid and base salts are otherwise
equivalent to their respective free base forms for purposes of the
invention.
[0049] All such acid and base salts are intended to be
pharmaceutically acceptable salts within the scope of the invention
and all acid and base salts are considered equivalent to the free
forms of the corresponding compounds for purposes of the
invention.
[0050] Alternatively, or additionally, it will become apparent that
the pharmaceutical composition may be administered alone or in
combination with other treatments, therapeutics or agents, either
simultaneously or sequentially dependent upon the condition to be
treated. For example, the progesterone antagonist, the SPRM or an
active metabolite thereof in the method of the invention may be
administered in association with an oestrogen either simultaneously
or sequentially. This association may allow, in certain conditions,
to increase bleeding control while minimizing oestrogen
exposure.
[0051] A further object of the present invention is to provide the
use of a progesterone antagonist, a SPRM, or an active metabolite
thereof for the preparation of a medicament in the treatment and/or
prevention of excessive uterine bleeding resulting from a
coagulation disorder, in a woman in need thereof.
[0052] The present invention also contemplates a kit for treating
and/or preventing excessive uterine bleeding resulting from a
coagulation disorder comprising the progesterone antagonist, the
SPRM or an active metabolite, optionally with reagents and/or
instructions for use.
[0053] Generally, the Kit comprises a container and a label or
package insert on or associated with the container. Suitable
containers include, for example, bottles, vials, syringes, etc. The
containers may be formed from a variety of materials such as glass
or plastic. The container holds the progesterone antagonist, the
SPRM or an active metabolite of the invention which is effective
for treating and/or preventing excessive uterine bleeding resulting
from a coagulation disorder and may have a sterile access port (for
example the container may be an intravenous solution bag or a vial
having a stopper pierceable by a hypodermic injection needle or an
aerosol spray device). The label or package insert indicates that
the composition is used for treating the condition of the
invention.
[0054] Alternatively, or additionally, the Kit may further comprise
a second (or third) container comprising a pharmaceutically
acceptable buffer, such as bacteriostatic water for injection
(BWFI), phosphate-buffered saline, Ringer's solution and dextrose
solution. It may further include other materials desirable fiom a
commercial and user standpoint, including other buffers, diluents,
filters, needles, and syringes.
[0055] Those skilled in the art will appreciate that the invention
described herein is susceptible to variations and modifications
other than those specifically described. It is to be understood
that the invention includes all such variations and modifications
without departing from the spirit or essential characteristics
thereof. The invention also includes all of the steps, features,
compositions and compounds referred to or indicated in this
specification, individually or collectively, and any and all
combinations or any two or more of said steps or features. The
present disclosure is therefore to be considered as in all aspects
illustrated and not restrictive, the scope of the invention being
indicated by the appended Claims, and all changes which come within
the meaning and range of equivalency are intended to be embraced
therein.
[0056] Various references are cited throughout this Specification,
each of which is incorporated herein by reference in its
entirety.
[0057] The foregoing description will be more fully understood with
reference to the following Examples. Such Examples, are, however,
exemplary of methods of practicing the present invention and are
not intended to limit the scope of the invention.
EXAMPLES
Example 1
[0058] A 19 year-old post-pubertal woman is consulting for fever,
infections, uterine bleeding, petechia and dyspnea. Blood test
identifies anemia (Hb 7.8 g/dL), normal leucocyte count (WBC 8657
cells/.mu.L) and thrombocytopenia (platelets: 13.476
cells/mm.sup.3). A bone marrow biopsy is performed which shows a
hypercellular bone marrow, with a monomorphic infiltration of
leukemic blasts and a marked reduction in normal bone marrow
elements. A diagnosis of Acute Lymphotic Leukemia is confirmed.
[0059] The patient undergoes blood and platelet transfusion to
correct for anemia and coagulation disorder. On the same day, she
starts taking orally 10 mg/day of CDB-2914. Uterine bleeding
quickly improved and 5 days following initiation of treatment,
bleeding is stopped. On that day, Hb is 9.9 g/dL; WBC 6345
cells/.mu.L; and platelet count is 42 000 cells/mm.sup.3,
[0060] She continues taking orally 10 mg/day of CDB2914 for
controlling abnormal uterine bleeding. Except for a few spotting,
she remains in amenorrhea (absence of uterine bleeding) despite
several episode of thrombopenia related to her conditions and
chemotherapy cycles.
[0061] After 3 months, she achieves remission, Hb is 13.1 g/dL;
leucocyte count is normal, platelet count is 176 000
cells/mm.sup.3. Bone marrow biopsy confirmed normalization. CDB2914
treatment is stopped, and regular, normal menstrual bleeding are
restored.
Example 2
[0062] A 31 year-old women is consulting for pneumonia. She reports
a recent history of night sweats and weight loss. Chest X ray shows
significant mediastinal adenopathies and a complete assessment for
lymphoma is undertaken. The diagnosis is a stage III of Hodgkin
disease. Her condition indicates chemotherapy (MOPP) and extended
irradiation. The main risk of the proposed therapy is bone marrow
suppression. This is life-threatening by exposing the patient to
severe infection and septicemia, but it is also associated with
severe thrombopenia and diffuse bleeding including uterine
bleeding.
[0063] In order to prevent uterine bleeding, before initiating
specific treatment for her Hodgkin disease, she is orally
administered 10 mg/day of CDB-2914. Following initiation of
chemotherapy and irradiation, severe bone marrow suppression is
recorded and the patient is admitted in aseptic unit. Despite
severe thrombopenia, the patient remains in amenorrhea. CBD2914
administration is maintained as long as coagulation parameters are
not normalized.
[0064] In both cases, reduction of bleeding allowed reduction in
platelet transfusion and total volume of blood transfused.
Example 3
[0065] A 42 year-old, moderate smoker women with a BMI at 32 is
treated with anticoagulant therapy for an episode of pulmonary
embolism resulting from a deep venous thrombosis in a leg. Despite
effort to adapt her anticoagulation therapy, her menstruations are
heavy (menorrhagia) and last for up to two weeks. Her Hb is at 9.2
gr/dL. Trans-vaginal ultrasound, endometrium biopsy and
hysteroscopy do not reveal an underlying condition which may cause
her menorraghia.
[0066] Her thrombo-embolic condition precludes any therapy with
oestrogens or progestins. Given, the absence of negative metabolic
and pro-thrombotic effect of SPRM, sheds orally administered 25
mg/day of Proellex.RTM. (CDB-4124). Uterine bleeding stopped after
a few days and the patient remain amenorrheic during the 12 weeks
of anticoagulation therapy. Her Hb progressively returned to normal
(>12 gd/dL).
[0067] After anticoagulation therapy is stopped, Proellex.RTM. is
stopped and the patients resumed normal menstruations.
* * * * *